Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...
After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...
Eli Lilly's ... weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread ...